Patents by Inventor Simeon Springer

Simeon Springer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEAD AND NECK SQUAMOUS CELL CARCINOMA ASSAYS
    Publication number: 20220220563
    Abstract: We queried DNA from saliva or plasma of 93 HNSCC patients, searching for somatic mutations or human papillomavirus genes, collectively referred to as tumor DNA. When both plasma and saliva were tested, tumor DNA was detected in 96% (95% CI, 84% to 99%) of 47 patients. The fractions of patients with detectable tumor DNA in early- and late-stage disease were 100% (n=10) and 95% (n=37), respectively. Saliva is preferentially enriched for tumor DNA from the oral cavity, whereas plasma is preferentially enriched for tumor DNA from the other sites. Tumor DNA in the saliva and plasma is a valuable biomarker for detection of HNSCC.
    Type: Application
    Filed: January 27, 2022
    Publication date: July 14, 2022
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Luis Diaz, Nickolas Papadopoulos, Nishant Agrawal, Yuxuan Wang, Simeon Springer
  • Head and neck squamous cell carcinoma assays
    Patent number: 11268153
    Abstract: We queried DNA from saliva or plasma of 93 HNSCC patients, searching for somatic mutations or human papillomavirus genes, collectively referred to as tumor DNA. When both plasma and saliva were tested, tumor DNA was detected in 96% (95% CI, 84% to 99%) of 47 patients. The fractions of patients with detectable tumor DNA in early- and late-stage disease were 100% (n=10) and 95% (n=37), respectively. Saliva is preferentially enriched for tumor DNA from the oral cavity, whereas plasma is preferentially enriched for tumor DNA from the other sites. Tumor DNA in the saliva and plasma is a valuable biomarker for detection of HNSCC.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: March 8, 2022
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Luis Diaz, Nickolas Papadopoulos, Nishant Agrawal, Yuxuan Wang, Simeon Springer
  • METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER
    Publication number: 20200377956
    Abstract: Provided herein are methods and materials for detecting and/or treating subject (e.g. a human) having cancer. In some embodiments, methods and materials for identifying a subject as having cancer (e.g., a localized cancer) are provided in which the presence of member(s) of two or more classes of biomarkers are detected. In some embodiments, methods and materials for identifying a subject as having cancer (e.g. a localized cancer) are provided in which the presence of member(s) of at least one class of biomarkers and the presence of aneuploidy are detected. In some embodiments, methods described herein provide increased sensitivity and/or specificity in the detection of cancer in a subject (e.g. a human).
    Type: Application
    Filed: August 7, 2018
    Publication date: December 3, 2020
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Joshua Cohen, Nickolas Papadopoulos, Anne Marie Lennon, Cristian Tomasetti, Yuxuan Wang, Georges Jabboure Netto, Rachel Karchin, Chris Douville, Samir Hanash, Simeon Springer, Arthur P Grollman, Kathleen Dickman
  • METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER
    Publication number: 20190256924
    Abstract: Provided herein are methods and materials for detecting and/or treating subject (e.g., a human) having cancer. In some embodiments, methods and materials for identifying a subject as having cancer (e.g., a localized cancer) are provided in which the presence of member(s) of two or more classes of biomarkers are detected. In some embodiments, methods and materials for identifying a subject as having cancer (e.g., a localized cancer) are provided in which the presence of member(s) of at least one class of biomarkers and the presence of aneuploidy are detected. In some embodiments, methods described herein provide increased sensitivity and/or specificity in the detection of cancer in a subject (e.g. a human).
    Type: Application
    Filed: January 17, 2019
    Publication date: August 22, 2019
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Joshua Cohen, Nickolas Papadopoulos, Anne Marie Lennon, Cristian Tomasetti, Yuxuan Wang, Georges Jabboure Netto, Rachel Karchin, Chris Douville, Samir Hanash, Simeon Springer, Arthur Grollman, Kathleen Dickman
  • HEAD AND NECK SQUAMOUS CELL CARCINOMA ASSAYS
    Publication number: 20180171413
    Abstract: We queried DNA from saliva or plasma of 93 HNSCC patients, searching for somatic mutations or human papillomavirus genes, collectively referred to as tumor DNA. When both plasma and saliva were tested, tumor DNA was detected in 96% (95% CI, 84% to 99%) of 47 patients. The fractions of patients with detectable tumor DNA in early- and late-stage disease were 100% (n=10) and 95% (n=37), respectively. Saliva is preferentially enriched for tumor DNA from the oral cavity, whereas plasma is preferentially enriched for tumor DNA from the other sites. Tumor DNA in the saliva and plasma is a valuable biomarker for detection of HNSCC.
    Type: Application
    Filed: June 16, 2016
    Publication date: June 21, 2018
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Luis Diaz, Nickolas Papadopoulos, Nishant Agrawal, Yuxuan Wang, Simeon Springer